Sign In
Buy CNTA
$40.50
+0 (+0%)
At Close: Jul 23, 2026
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?
10:31am, Tuesday, 26'th Dec 2023
Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.
Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 13'th Dec 2023
BOSTON and LONDON, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines f
BOSTON and LONDON, Dec. 10, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced new data from an additional 52-weeks of continuous treatment from the third year (Part
Does Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) Have the Potential to Rally 40.85% as Wall Street Analysts Expect?
11:17am, Tuesday, 05'th Dec 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 40.9% in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA). While the effectiveness of this highly sought-after
Wall Street Analysts Predict a 35.92% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know
11:16am, Thursday, 16'th Nov 2023
The consensus price target hints at a 35.9% upside potential for Centessa Pharmaceuticals PLC Sponsored ADR (CNTA). While empirical research shows that this sought-after metric is hardly effective, an
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
04:05pm, Monday, 13'th Nov 2023
BOSTON and LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are trans
BOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that new data from an additional 52-weeks of continuous treatment from the third year (
BOSTON and LONDON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are trans
- Preclinical data demonstrated significant activity at low doses of ORX750 in highly predictive translational models of Narcolepsy Type 1 (NT1)
Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why
12:01pm, Monday, 04'th Sep 2023
Centessa (CNTA) shares rise significantly in the past three months due to the encouraging progress in the development of its lead pipeline candidate, SerpinPC, which is currently in mid-late-stage stu
Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress
05:08pm, Wednesday, 23'rd Aug 2023
Oral presentation to include preclinical profile for ORX750, Centessa's first orexin agonist development candidate for the treatment of narcolepsy and other sleep disorders Oral presentation to includ
Centessa Pharmaceuticals: Pipeline Progresses As PRESent-2 Initiated
11:58am, Thursday, 17'th Aug 2023
Centessa Pharmaceuticals takes a unique "asset-centric" approach in the biopharmaceutical industry, offering advantages such as reduced risk, improved efficiency, and greater potential for innovation.
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 24'th May 2023
BOSTON and LONDON, May 24, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines f
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
08:00am, Monday, 27'th Mar 2023
BOSTON and LONDON, March 27, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transfor
Should You Buy Centessa Pharmaceuticals (CNTA) Ahead of Earnings?
09:54am, Thursday, 23'rd Mar 2023
Centessa Pharmaceuticals (CNTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
